Bioavailability of Encapsulated Omega-3 Fatty Acids
NCT01940679 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2014-03-04
Summary
Omega-3 fatty acids (n-3s), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have anti-inflammatory properties and other documented beneficial health effects that could warrant n-3 fortification of combat rations. However, military combat rations must meet rigorous shelf-stability guidelines (e.g.,, 3 years at 80°F or 6 months at 100°F), which is problematic for natural food sources of n-3s (e.g., oil and fish), which degrade when exposed to high temperatures and prolonged shelf-storage. Encapsulation, e.g., coating freeze dried n-3s with gelatin, can prevent this degradation, and Natick Soldier Research, Development and Engineering Center's (NSRDEC) Combat Feeding Directorate used encapsulated n-3 technology to produce n-3 enriched ration items that withstand environmental stressors and meet shelf-life specifications for military rations. However, the bioavailability of the encapsulated n-3s in these rations is unknown, particularly when they are incorporated into high-protein food items and exposed to high temperatures and prolonged storage. In this randomized, cross-over study, civilian and/or military personnel will be asked to consume: 1) a high protein food item enriched with encapsulated n-3s (600 mg) and previously stored for 6 months at 100°F; 2) a low-protein food item enriched with encapsulated n-3s (600 mg) and previously stored for 6 months at 100°F; 3) a high protein food item with encapsulated n-3s (600 mg) that was not subjected to high-temperature and prolonged storage; and, 4) a low-protein food item with encapsulated n-3s (600 mg) that was not subjected to high temperature and prolonged storage. Serial blood sampling to measure acute changes in the circulating fatty acid profile will occur in the hour before and 6 hours after consumption of each ration component. The only known risks, which this study presents to participants, are those associated with venous catheter placement. The results will help military ration developers determine the ration components best suited for n-3 fortification.
Conditions
- Bioavailability of Omega-3s in Military Rations
Interventions
- DIETARY_SUPPLEMENT
-
encapsulated 600 mg EPA/DHA
encapsulated 600 mg EPA/DHA
Sponsors & Collaborators
-
Combat Feeding Directorate at Natick Soldier, Research, Development and Engineering Center
collaborator UNKNOWN -
United States Army Research Institute of Environmental Medicine
lead FED
Principal Investigators
-
Tracey J Smith, PhD · U.S. Army Research Institute of Environmental Medicine
Study Design
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-09-30
- Primary Completion
- 2013-12-31
- Completion
- 2013-12-31
Countries
- United States
Study Locations
More Related Trials
-
Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride
NCT01488747 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Acute Bioavailability of EPA and DHA From a DietarySupplement in Healthy Men and Women
NCT02865044 ·Status: COMPLETED ·Phase: NA
-
Effects of Omega-3 Fatty Acids in Ambient Air Pollution Exposure in Healthy Adults
NCT02921048 ·Status: COMPLETED
-
A Dose Response Investigation of Docosahexaenoic Acid (DHA)
NCT06294067 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation
NCT01078909 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA
NCT06629103 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults
NCT02514070 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate
NCT02092649 ·Status: COMPLETED ·Phase: NA
-
Cardiometabolic Benefits of Omega-3 Polyunsaturated Fatty Acids
NCT03378232 ·Status: COMPLETED ·Phase: NA
-
Bioavailability of EPA + DHA in a SMEDS Formulation
NCT03443076 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil
NCT00988585 ·Status: COMPLETED ·Phase: PHASE1
-
An Evaluation of Omega-3 Fatty Acid
NCT03017651 ·Status: COMPLETED ·Phase: PHASE1
-
A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products
NCT01960660 ·Status: COMPLETED ·Phase: NA
-
Plasma Diurnal Variation in and Absorption of EPA and DHA
NCT02661698 ·Status: COMPLETED ·Phase: NA
-
Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers
NCT05121766 ·Status: TERMINATED ·Phase: PHASE1
-
Bioavailability Study of Long Chain Omega-3 Fatty Acids From a Gastric Stable Emulsion
NCT01061554 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA)
NCT04159532 ·Status: COMPLETED ·Phase: PHASE4
-
Fish Oils and Soybean Lecithin Supplementation Modulate Immune Function in Runners
NCT03364699 ·Status: COMPLETED ·Phase: NA
-
Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids
NCT02670382 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics of Omega-3 Monoglycerides
NCT04382027 ·Status: COMPLETED ·Phase: NA
-
A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and Placebo
NCT07241377 ·Status: RECRUITING ·Phase: PHASE3
-
Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes
NCT02610270 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Bioavailability of Fatty Acids From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.
NCT02089165 ·Status: COMPLETED ·Phase: PHASE2
-
Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?
NCT01091714 ·Status: COMPLETED ·Phase: PHASE4
-
Investigating the Effect of 4-week Omega-3 Polyunsaturated Fatty Acid Supplementation on Inflammation
NCT03210805 ·Status: UNKNOWN ·Phase: NA